Individualized pharmaceutical care for a patient after pancreaticoduodenectomy with trypsin replacement nutritional therapy: A case report.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
26 Aug 2022
26 Aug 2022
Historique:
entrez:
31
8
2022
pubmed:
1
9
2022
medline:
2
9
2022
Statut:
ppublish
Résumé
Optimal nutritional therapy for pancreaticoduodenectomy (PD) has been debated; however, little is known about key points of pancreatin enteric-coated capsule administration, a critical component of the PD treatment regimen. Patients often report elevations in tablet platoon and steatorrhea, and steatorrhea may adversely affect nutritional therapy for PD. Herein, we report a case of individualized pharmaceutical care for a patient after PD with trypsin replacement nutritional therapy. After PD with trypsin replacement nutritional therapy, the patient developed acute steatorrhea. Individualized pharmaceutical care was provided by clinical pharmacists to address intolerance to pancreatin enteric-coated capsules following PD. The clinical pharmacist's integration into the patient's treatment plan enhanced pharmacotherapy optimization, especially through pharmacokinetic monitoring and interventions related to nutritional therapy. Pharmaceutical care by clinical pharmacists aids in ensuring the safety and efficacy of drugs and nutritional treatment. Clinical pharmacists should be members of the nutrition support team.
Identifiants
pubmed: 36042676
doi: 10.1097/MD.0000000000030209
pii: 00005792-202208260-00095
pmc: PMC9410642
doi:
Substances chimiques
Pancreatin
8049-47-6
Trypsin
EC 3.4.21.4
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30209Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Trapnell BC, Chen S, Khurmi R, et al. Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy. Chron Respir Dis. 2020;17:147997311990061404143044.
Barto TL, Morency CF, Schaap N, et al. Intestinal absorption of lipids using a pancreatic enzyme-free nutritional supplement in patients with cystic fibrosis: a randomized, double-blind, crossover pilot trial. Nutrients. 2022;14:680.
Min C, Kan Q. Research progress of standardized pharmaceutical care model. China Pharmaceutical Co. 2020;29:95–8.
Gianotti L, Besselink MG, Sandini M, et al. Nutritional support and therapy in pancreatic surgery: a position paper of the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2018;164:1035–48.
Yuanchong J, Yuan D, Chen H, et al. Research progress of total pancreatectomy. Chin J General Surg2019;9:819–22.
Kuhn RJ, Gelrud A, Munck A, et al. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency. Adv Ther. 2010;27:895–916.
Shlieout G, Koerner A, Maffert M, et al. Administration of CREON(R) pancrelipase pellets via gastrostomy tube is feasible with no loss of gastric resistance or lipase activity: an in vitro study. Clin Drug Investig. 2011;31:e1–7.
Kuhn RJ, Gelrud A, Munck A, et al. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency. Adv Ther. 2010;27:895–916.
Xiaohong W. Study on disintegration time limit of four enteric-soluble capsules. Modern Med Health. 2008;15:2346.
Aloulou A, Puccinelli D, Sarles J, et al. In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability. Aliment Pharmacol Ther. 2008;27:283–92.
Gan KH, Geus WP, Bakker W, et al. In vitro dissolution profiles of enteric-coated microsphere/microtablet pancreatin preparations at different pH values. Aliment Pharmacol Ther. 1996;10:771–5.